Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Change in Accured Expenses (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Change in Accured Expenses data on record, last reported at $971647.0 in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 168.83% year-over-year to $971647.0; the TTM value through Sep 2025 reached $5.5 million, up 2201.34%, while the annual FY2024 figure was $1.9 million, 46.35% up from the prior year.
  • Change in Accured Expenses reached $971647.0 in Q3 2025 per CAPR's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.2 million in Q4 2022 and bottomed at -$541709.0 in Q4 2023.
  • Average Change in Accured Expenses over 5 years is $494315.8, with a median of $405717.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: tumbled 229.82% in 2022, then soared 83134.6% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $102308.0 in 2021, then surged by 2083.16% to $2.2 million in 2022, then plummeted by 124.25% to -$541709.0 in 2023, then soared by 406.44% to $1.7 million in 2024, then tumbled by 41.47% to $971647.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $971647.0 in Q3 2025, $1.5 million in Q2 2025, and $1.3 million in Q1 2025.